FDA approves Arcutis’ skin foam for seborrheic dermatitis

By admin Dec20,2023

The US Food and Drug Administration (FDA) has approved a topical foam developed by Arcutis Biotherapeutics and branded as Zoryve for the skin condition seborrheic dermatitis in people aged nine years and up.

By admin

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *